Overview

ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2022-05-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Collaborator:

Orion Corporation, Orion Pharma

Treatments:

Androgens
Docetaxel
Hormones